Clinical Trial Update: Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating atomoxetine for adolescents with ADHD and marijuana abuse has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Disorder with Hyperactivity
• Marijuana Abuse

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Attention Deficit Disorder With Hyperactivity, Marijuana Abuse | Phase 2 | Status: COMPLETED